DV1-DNA vaccine

DV1-DNA vaccine (also known as deltaV1-DNA vaccine) is an experimental DNA vaccine candidate developed by the National Cancer Institute (NCI) of the National Institutes of Health (NIH). It encodes a V1-deleted (ΔV1) envelope (Env) glycoprotein of HIV-1 or SIV. The vaccine is designed to be used as a prime in a prime-boost immunization regimen (typically primed with DV1-DNA and boosted with ALVAC and/or DV1-gp120 protein) to prevent HIV infection. By deleting the variable loop 1 (V1) of the envelope protein, the vaccine exposes conserved epitopes, enhancing the induction of protective immune responses, including immunomodulatory Tr1 CD4+ T cells and mucosal memory-like NK cells, thereby reducing the risk of viral acquisition.

Other names

DV1 DNA vaccineDV-1 DNA vaccineDV 1 DNA vaccineSIV gp160 DV1 DNAV1-deleted DNA vaccineV-1-deleted DNA vaccineV 1-deleted DNA vaccineV1-deleted HIV vaccine candidateV-1-deleted HIV vaccine candidateV 1-deleted HIV vaccine candidatedeltaV1 DNA vaccinedeltaV-1 DNA vaccinedeltaV 1 DNA vaccinedeltaV1-DNA vaccinedeltaV-1-DNA vaccinedeltaV 1-DNA vaccineΔV1 DNA vaccineΔV1-DNA vaccine